Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1Breast 1

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Dexamethasone 126daratumumab 75Lenalidomide 72Bortezomib 62pomalidomide 47Cyclophosphamide 42carfilzomib 41Calcium Dobesilate 36Specimen Handling 34Biopsy 30Magnetic Resonance Spectroscopy 28belantamab mafodotin 25fludarabine 21isatuximab 20dexamethasone acetate 18dexamethasone 21-phosphate 18auricularum 18Melphalan 18iberdomide 17talquetamab 16fludarabine phosphate 12selinexor 11elotuzumab 10X-Rays 10tocilizumab 9Nivolumab 8Whole-Body Irradiation 7Sirolimus 7Crizotinib 7trametinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Injections, Subcutaneous × Plasma cell × 90 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06223516 2026-03-27

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

AbbVie

Phase 1 Active not recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡